Additive hormonal therapy in women with advanced breast cancer

J. N. Ingle

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A great deal of work has been done over the last decade in the assessment of additive hormonal treatment approaches in women with advanced breast cancer. This work has been prompted by a number of factors which include: (1) the introduction of new hormonal agents, (2) increased knowledge of the physiologic actions of several hormonal agents, (3) the development of hormonal receptor assays to better predict the probability of hormonal responsiveness in a given patient, and (4) the apparent plateau in efficacy of cytotoxic chemotherapeutic approaches. The hormonal agents that have been studied most extensively in the recent past include tamoxifen (an antiestrogen), aminoglutethimide (an aromatase inhibitor), and medroxyprogesterone acetate (a progestin). In postmenopausal women, several agents exist that appear about equal in efficacy; but, currently, tamoxifen appears to be preferred as the initial hormonal treatment, primarily because of its low incidence of side effects. Studies involving combination hormonal therapy have produced interesting results, but further work is needed to establish superiority over tamoxifen alone. In premenopausal women, tamoxifen does have antitumor activity in some patients but has not been established as a replacement for oophorectomy. Properly conducted comparative trials will remain essential for the determination of the proper place of newer hormonal therapy approaches in clinical practice.

Original languageEnglish (US)
Pages (from-to)766-777
Number of pages12
JournalCancer
Volume53
Issue number3 SUPPL.
StatePublished - 1984

Fingerprint

Tamoxifen
Breast Neoplasms
Aminoglutethimide
Medroxyprogesterone Acetate
Aromatase Inhibitors
Estrogen Receptor Modulators
Ovariectomy
Progestins
Therapeutics
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ingle, J. N. (1984). Additive hormonal therapy in women with advanced breast cancer. Cancer, 53(3 SUPPL.), 766-777.

Additive hormonal therapy in women with advanced breast cancer. / Ingle, J. N.

In: Cancer, Vol. 53, No. 3 SUPPL., 1984, p. 766-777.

Research output: Contribution to journalArticle

Ingle, JN 1984, 'Additive hormonal therapy in women with advanced breast cancer', Cancer, vol. 53, no. 3 SUPPL., pp. 766-777.
Ingle, J. N. / Additive hormonal therapy in women with advanced breast cancer. In: Cancer. 1984 ; Vol. 53, No. 3 SUPPL. pp. 766-777.
@article{eeb87943c93447608284bad20f2f320d,
title = "Additive hormonal therapy in women with advanced breast cancer",
abstract = "A great deal of work has been done over the last decade in the assessment of additive hormonal treatment approaches in women with advanced breast cancer. This work has been prompted by a number of factors which include: (1) the introduction of new hormonal agents, (2) increased knowledge of the physiologic actions of several hormonal agents, (3) the development of hormonal receptor assays to better predict the probability of hormonal responsiveness in a given patient, and (4) the apparent plateau in efficacy of cytotoxic chemotherapeutic approaches. The hormonal agents that have been studied most extensively in the recent past include tamoxifen (an antiestrogen), aminoglutethimide (an aromatase inhibitor), and medroxyprogesterone acetate (a progestin). In postmenopausal women, several agents exist that appear about equal in efficacy; but, currently, tamoxifen appears to be preferred as the initial hormonal treatment, primarily because of its low incidence of side effects. Studies involving combination hormonal therapy have produced interesting results, but further work is needed to establish superiority over tamoxifen alone. In premenopausal women, tamoxifen does have antitumor activity in some patients but has not been established as a replacement for oophorectomy. Properly conducted comparative trials will remain essential for the determination of the proper place of newer hormonal therapy approaches in clinical practice.",
author = "Ingle, {J. N.}",
year = "1984",
language = "English (US)",
volume = "53",
pages = "766--777",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Additive hormonal therapy in women with advanced breast cancer

AU - Ingle, J. N.

PY - 1984

Y1 - 1984

N2 - A great deal of work has been done over the last decade in the assessment of additive hormonal treatment approaches in women with advanced breast cancer. This work has been prompted by a number of factors which include: (1) the introduction of new hormonal agents, (2) increased knowledge of the physiologic actions of several hormonal agents, (3) the development of hormonal receptor assays to better predict the probability of hormonal responsiveness in a given patient, and (4) the apparent plateau in efficacy of cytotoxic chemotherapeutic approaches. The hormonal agents that have been studied most extensively in the recent past include tamoxifen (an antiestrogen), aminoglutethimide (an aromatase inhibitor), and medroxyprogesterone acetate (a progestin). In postmenopausal women, several agents exist that appear about equal in efficacy; but, currently, tamoxifen appears to be preferred as the initial hormonal treatment, primarily because of its low incidence of side effects. Studies involving combination hormonal therapy have produced interesting results, but further work is needed to establish superiority over tamoxifen alone. In premenopausal women, tamoxifen does have antitumor activity in some patients but has not been established as a replacement for oophorectomy. Properly conducted comparative trials will remain essential for the determination of the proper place of newer hormonal therapy approaches in clinical practice.

AB - A great deal of work has been done over the last decade in the assessment of additive hormonal treatment approaches in women with advanced breast cancer. This work has been prompted by a number of factors which include: (1) the introduction of new hormonal agents, (2) increased knowledge of the physiologic actions of several hormonal agents, (3) the development of hormonal receptor assays to better predict the probability of hormonal responsiveness in a given patient, and (4) the apparent plateau in efficacy of cytotoxic chemotherapeutic approaches. The hormonal agents that have been studied most extensively in the recent past include tamoxifen (an antiestrogen), aminoglutethimide (an aromatase inhibitor), and medroxyprogesterone acetate (a progestin). In postmenopausal women, several agents exist that appear about equal in efficacy; but, currently, tamoxifen appears to be preferred as the initial hormonal treatment, primarily because of its low incidence of side effects. Studies involving combination hormonal therapy have produced interesting results, but further work is needed to establish superiority over tamoxifen alone. In premenopausal women, tamoxifen does have antitumor activity in some patients but has not been established as a replacement for oophorectomy. Properly conducted comparative trials will remain essential for the determination of the proper place of newer hormonal therapy approaches in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0021367312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021367312&partnerID=8YFLogxK

M3 - Article

C2 - 6229323

AN - SCOPUS:0021367312

VL - 53

SP - 766

EP - 777

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3 SUPPL.

ER -